• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当代转移性肾细胞癌的治疗。

Contemporary treatment of metastatic renal cell carcinoma.

机构信息

Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland.

Department of Urology, The John Paul II District Hospital in Kolbuszowa, Kolbuszowa, Poland.

出版信息

Med Oncol. 2018 Oct 27;35(12):156. doi: 10.1007/s12032-018-1217-1.

DOI:10.1007/s12032-018-1217-1
PMID:30368624
Abstract

Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20-30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that-with the introduction of new drugs-the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.

摘要

肾细胞癌是全球第 14 常见的癌症。它是一组具有异质性的组织病理学实体,其中最常见的是透明细胞肾细胞癌。约 20-30%的患者最初表现为转移性疾病,另外 20%的患者在根治性手术治疗后会进展。对于无法进行手术治疗的转移性疾病仍然是无法治愈的。大量研究表明,随着新药的引入,转移性疾病的治疗结果已经得到改善。新疗法的开发以及程序的优化和个体化使我们有望在这一领域取得进一步进展。

相似文献

1
Contemporary treatment of metastatic renal cell carcinoma.当代转移性肾细胞癌的治疗。
Med Oncol. 2018 Oct 27;35(12):156. doi: 10.1007/s12032-018-1217-1.
2
What advances have been made in immune-therapy for renal cell carcinoma?肾细胞癌免疫治疗取得了哪些进展?
Future Oncol. 2017 Apr;13(8):665-668. doi: 10.2217/fon-2017-0026. Epub 2017 Feb 10.
3
[Immunotherapy of renal cell cancer].[肾细胞癌的免疫疗法]
Magy Onkol. 2017 Jun 6;61(2):126-131. Epub 2017 Apr 23.
4
Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.转移性肾细胞癌的当前和新兴治疗靶点。
Curr Oncol Rep. 2018 Apr 2;20(5):41. doi: 10.1007/s11912-018-0684-z.
5
New therapeutic developments in renal cell cancer.肾细胞癌的新治疗进展。
Crit Rev Oncol Hematol. 2009 Jan;69(1):56-63. doi: 10.1016/j.critrevonc.2008.07.007. Epub 2008 Aug 26.
6
Emerging therapeutic approaches in renal cell carcinoma.肾细胞癌的新兴治疗方法。
Expert Rev Anticancer Ther. 2015;15(11):1305-14. doi: 10.1586/14737140.2015.1090315. Epub 2015 Sep 17.
7
T-cell checkpoint inhibitors in metastatic renal cell carcinoma.转移性肾细胞癌中的T细胞检查点抑制剂
Curr Opin Urol. 2015 Sep;25(5):411-5. doi: 10.1097/MOU.0000000000000199.
8
High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?高剂量白细胞介素-2治疗转移性肾细胞癌:首个抗肿瘤免疫疗法能否重塑?
Immunotherapy. 2014;6(9):955-8. doi: 10.2217/imt.14.78.
9
The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.转移性肾细胞癌免疫治疗的过去、现在与未来
Anticancer Res. 2019 Jun;39(6):2683-2687. doi: 10.21873/anticanres.13393.
10
Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.基于干扰素-α的免疫疗法在原发性肿瘤原位的转移性肾细胞癌患者中的应用。
Jpn J Clin Oncol. 2012 Feb;42(2):113-9. doi: 10.1093/jjco/hyr176. Epub 2011 Nov 29.

引用本文的文献

1
Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma.立体定向放射治疗用于治疗肾细胞癌腺性转移灶
Adv Radiat Oncol. 2025 Jun 13;10(9):101835. doi: 10.1016/j.adro.2025.101835. eCollection 2025 Sep.
2
NK cells in renal cell carcinoma and its implications for CAR-NK therapy.肾细胞癌中的自然杀伤细胞及其对嵌合抗原受体自然杀伤细胞疗法的影响。
Front Cell Dev Biol. 2025 Feb 20;13:1532491. doi: 10.3389/fcell.2025.1532491. eCollection 2025.
3
pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation.

本文引用的文献

1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
2
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.卡博替尼对比舒尼替尼作为中危或高危转移性肾细胞癌的初始治疗(Alliance A031203 CABOSUN 随机试验):独立审查的无进展生存和总生存更新。
Eur J Cancer. 2018 May;94:115-125. doi: 10.1016/j.ejca.2018.02.012. Epub 2018 Mar 20.
3
他克莫司 pH 响应性嵌段共聚物胶束的制备、表征及抗肿瘤活性评价。
Int J Nanomedicine. 2024 Sep 23;19:9821-9841. doi: 10.2147/IJN.S469913. eCollection 2024.
4
Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review.治疗肾细胞癌不同转移部位的选择:综述。
Medicine (Baltimore). 2024 May 24;103(21):e38268. doi: 10.1097/MD.0000000000038268.
5
GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.GHITM 通过 Notch 信号调控肾癌细胞的恶性表型和对 PD-1 阻断的敏感性。
J Cell Mol Med. 2024 Apr;28(8):e18290. doi: 10.1111/jcmm.18290.
6
Clinically Silent, Metastatic Renal Cell Carcinoma Detected on Routine Screening Mammogram: A Report of a Rare Case and Review of Literature.常规筛查乳房X光检查发现的临床隐匿性转移性肾细胞癌:1例罕见病例报告及文献复习
Cureus. 2023 Nov 6;15(11):e48352. doi: 10.7759/cureus.48352. eCollection 2023 Nov.
7
Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment.中国肾细胞癌患者对药物的偏好和支付意愿:一项离散选择实验。
Patient. 2024 Jan;17(1):97-108. doi: 10.1007/s40271-023-00659-2. Epub 2023 Nov 29.
8
Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer.m6A 修饰在调控癌症中 PI3K/AKT 信号通路中的作用。
J Transl Med. 2023 Nov 1;21(1):774. doi: 10.1186/s12967-023-04651-0.
9
Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022.2003-2022 年肾细胞癌免疫治疗进展的文献计量学分析。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2243669. doi: 10.1080/21645515.2023.2243669.
10
Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.TACE+舒尼替尼与舒尼替尼治疗不可切除的晚期肾细胞癌的疗效和安全性分析:一项回顾性研究。
BMC Cancer. 2023 Mar 24;23(1):270. doi: 10.1186/s12885-023-10754-0.
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
帕唑帕尼辅助治疗对比安慰剂用于局限性或局部进展性肾细胞癌患者肾切除术后的随机III期试验
J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.
4
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.辅助舒尼替尼治疗肾切除术后高危肾细胞癌。
N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.
5
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.转移性肾细胞癌患者通过序贯靶向治疗改善生存终点。
Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10.
6
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肾细胞癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v58-v68. doi: 10.1093/annonc/mdw328.
7
Metastasis therapies for renal cancer.肾癌的转移治疗
Curr Opin Urol. 2016 Nov;26(6):566-72. doi: 10.1097/MOU.0000000000000330.
8
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.卡博替尼对比依维莫司治疗晚期肾细胞癌(METEOR):一项随机、开放标签、III 期临床试验的最终结果。
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
9
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.舒尼替尼或索拉非尼辅助治疗高危、非转移性肾细胞癌(ECOG-ACRIN E2805):一项双盲、安慰剂对照、随机3期试验。
Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9.
10
Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection.立体定向放射外科治疗肾癌脑转移:预后因素及全脑放疗和手术切除的作用
J Oncol. 2015;2015:636918. doi: 10.1155/2015/636918. Epub 2015 Nov 19.